You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Lytix Biopharma’s oncolytic immunotherapy ruxotemitide shows strong phase II data
Lytix Biopharma's partner Verrica Pharmaceuticals has presented new Phase II results for ruxotemitis at the 40th Annual Meeting of the Society for Immunotherapy of Cancer. At the same time, Lytix itself presented preliminary data from...